Promising Penny Stocks To Consider In August 2025

As the U.S. stock market continues its rally, with major indices like the S&P 500 and Nasdaq hitting new highs, investors are exploring diverse opportunities to capitalize on this momentum. Penny stocks, often associated with smaller or newer companies, remain a compelling area for those looking to uncover hidden value and growth potential. Despite being an older term in the investment lexicon, these stocks can offer intriguing opportunities when backed by robust financials and strategic positioning within their industries.

Top 10 Penny Stocks In The United States

Click here to see the full list of 400 stocks from our US Penny Stocks screener.

Here we highlight a subset of our preferred stocks from the screener.

Erasca (ERAS)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Erasca, Inc. is a clinical-stage precision oncology company dedicated to discovering, developing, and commercializing therapies for RAS/MAPK pathway-driven cancers, with a market cap of approximately $442.49 million.

Operations: Erasca, Inc. currently does not report any revenue segments.

Market Cap: $442.49M

Erasca, Inc., a pre-revenue clinical-stage precision oncology company, recently reported a reduced net loss of US$33.88 million for Q2 2025 compared to the previous year. Despite being unprofitable with negative return on equity and no significant revenue streams, the company remains debt-free and has sufficient cash runway for over two years. Recent developments include FDA clearance for an investigational drug targeting KRAS-mutant tumors and filing a US$500 million shelf registration to potentially raise capital through various securities. The stock exhibits high volatility but has not experienced meaningful shareholder dilution recently.

• Take a closer look at Erasca's potential here in our financial health report.
• Review our growth performance report to gain insights into Erasca's future.

EVgo (EVGO)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: EVgo, Inc. owns and operates a direct current fast charging network for electric vehicles in the United States, with a market cap of approximately $1.16 billion.

Operations: The company's revenue is derived from its Retail - Gasoline & Auto Dealers segment, totaling $308.37 million.

Market Cap: $1.16B

EVgo, Inc., with a market cap of US$1.16 billion, is expanding its fast charging network for electric vehicles in the U.S., supported by a recent US$225 million credit facility from global banks. Despite being unprofitable and experiencing increased losses over the past five years, EVgo's revenue is projected to grow significantly. The company reported Q2 2025 sales of US$98.03 million, up from US$66.62 million a year ago, though net losses widened to US$13 million. While short-term liabilities are covered by assets, long-term liabilities remain uncovered; insider selling has been significant recently.

• Navigate through the intricacies of EVgo with our comprehensive balance sheet health report here.
• Gain insights into EVgo's future direction by reviewing our growth report.

Sana Biotechnology (SANA)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Sana Biotechnology, Inc. is a biotechnology company that focuses on utilizing engineered cells as medicines in the United States, with a market cap of approximately $791.90 million.

Operations: Sana Biotechnology, Inc. currently does not report any revenue segments.

Market Cap: $791.9M

Sana Biotechnology, Inc., with a market cap of US$791.90 million, remains pre-revenue and unprofitable but has managed to reduce losses over the past five years by 4.5% annually. The company recently reported a net loss of US$93.8 million for Q2 2025, up from US$50.29 million the previous year, and completed a follow-on equity offering raising approximately US$75 million to extend its cash runway beyond five months. Despite high volatility in its share price and short-term assets not covering long-term liabilities, Sana's strategic advancements include promising clinical results for its hypoimmune technology in diabetes treatment studies.

• Dive into the specifics of Sana Biotechnology here with our thorough balance sheet health report.
• Assess Sana Biotechnology's future earnings estimates with our detailed growth reports.

Next Steps

• Get an in-depth perspective on all 400 US Penny Stocks by using our screener here.
• Contemplating Other Strategies? AI is about to change healthcare. These 25 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com